SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q4 FY21 results · Jan–Mar 2021
SMS Pharmaceuticals reported revenue from operations of ₹171.29 crore (up 77.6% from Q4 FY20) and net profit of ₹23.14 crore (up 270.3% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 171.29 | 96.47 | +77.6% | 148.87 | +15.1% |
| Other income | 1.30 | 3.09 | −57.8% | 0.86 | +52.3% |
| Total income | 172.59 | 99.55 | +73.4% | 149.72 | +15.3% |
| Profit before tax | 34.31 | 8.63 | +297.5% | 26.75 | +28.3% |
| Net profit for the period | 23.14 | 6.25 | +270.3% | 18.32 | +26.3% |
| EPS, basic (₹) | 2.73 | 0.74 | +268.9% | 2.16 | +26.4% |
| Net margin (%) | 13.5 | 6.5 | 12.3 |
Standalone
- Filed with BSE
- 31 May 2021, 11:48 IST
- Board meeting
- 28 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE